<DOC>
	<DOCNO>NCT03030625</DOCNO>
	<brief_summary>The aim study determine efficacy safety implementation program `` image-guided focal Intensification dose intraprostatic dominant lesion `` men localized prostate cancer ( PCa ) intermediate high risk ( criterion NCCN ) eligible receive radiotherapy Department Radiation Oncology HUP within establish dose escalation protocol intensity modulate image-guided radiotherapy ( IMRT / IGRT ) .</brief_summary>
	<brief_title>VMAT Dominant Intraprostatic Lesion</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>Male &gt; 18 year old histologic diagnostic prostate adenocarcinoma Clinical stage cT2a‐T3b N0‐1 M0 ( AJCC 7 th edition ) PSA &lt; 100 ng/ml Gleason score 6‐10 Life expectancy &gt; 5 year Patients accept radiotherapy treatment Patients provide write informed consent participate trial Transurethral resection prostate prior prostate surgery Previous pelvic radiotherapy Urethral stenosis without prior dilation IPSS &gt; 15 Rectal diverticuli rectal vascular malformation Metastatic disease Severe psychiatric medical condition could hamper treatment followup</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Prostate Cancer</keyword>
	<keyword>VMAT</keyword>
	<keyword>Dominant Intraprostatic Lesion</keyword>
	<keyword>Intensity modulate radiotherapy</keyword>
</DOC>